AI assistant
Jade Biosciences, Inc. — Director's Dealing 2021
Jun 30, 2021
33383_dirs_2021-06-29_579673e1-809c-4c28-8d1d-04a2bcb7d81f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-06-29
Reporting Person: RA CAPITAL MANAGEMENT, L.P. (Director, 10% Owner)
Reporting Person: RA Capital Healthcare Fund LP (Director, 10% Owner)
Reporting Person: RA Capital Nexus Fund, L.P. (Director)
Reporting Person: Kolchinsky Peter (Director, 10% Owner)
Reporting Person: Shah Rajeev M. (Director, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 241467 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series Seed Preferred Stock | $ | Common Stock (1287825) | Indirect | ||
| Series A Preferred Stock | $ | Common Stock (3948976) | Indirect |
Footnotes
F1: Shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund")
F2: Includes (a) 2,650,562 shares of Series A Preferred Stock held by the Fund, (b) 987,244 shares of Series A Preferred Stock held by RA Capital Nexus Fund, L.P. (the "Nexus Fund") and (c) 311,170 shares of Series A Preferred Stock held by a separately managed account (the "Account").
F3: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Nexus Fund and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4: Each share of Series Seed Preferred Stock and Series A Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-3.1060103 basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.